Tokyo, Japan

Hiroko Koda

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignee: Daiichi Pharmaceutical Co., Ltd.. Active years: 1996.


% Patents Active = 100.0


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hiroko Koda: Innovator in Antimicrobial Agents

Introduction

Hiroko Koda is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of antimicrobial agents. With a total of 2 patents, her work has garnered attention for its potential impact on antibiotic treatments.

Latest Patents

Hiroko Koda's latest patents focus on carbapenem derivatives, which are known for their potent and stable antimicrobial properties. These derivatives include a specific formula where R1 can be a hydrogen atom or an alkyl group, and COOR2 represents a carboxyl group or its derivatives. The compounds demonstrate strong antibacterial activity against various strains, including Pseudomonas aeruginosa, and are designed to be safe and stable against hydrolases such as dehyropeptidase.

Career Highlights

Throughout her career, Hiroko has worked with notable companies such as Daiichi Pharmaceutical Co., Ltd. and has collaborated with esteemed professionals in her field. Her innovative approach to antibiotic development has positioned her as a key figure in pharmaceutical research.

Collaborations

Hiroko has collaborated with several professionals, including Makoto Takemura and Toshiyuki Nishi, contributing to her success in the industry.

Conclusion

Hiroko Koda's contributions to antimicrobial research highlight her role as an influential inventor in the pharmaceutical field. Her innovative carbapenem derivatives represent a significant advancement in antibiotic development, showcasing her dedication to improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…